IL125953A0 - Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy - Google Patents
Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapyInfo
- Publication number
- IL125953A0 IL125953A0 IL12595398A IL12595398A IL125953A0 IL 125953 A0 IL125953 A0 IL 125953A0 IL 12595398 A IL12595398 A IL 12595398A IL 12595398 A IL12595398 A IL 12595398A IL 125953 A0 IL125953 A0 IL 125953A0
- Authority
- IL
- Israel
- Prior art keywords
- administering
- methods
- receptor antagonists
- dopamine agonist
- ampa receptor
- Prior art date
Links
- 229940098747 AMPA receptor antagonist Drugs 0.000 title 1
- 239000000775 AMPA receptor antagonist Substances 0.000 title 1
- 208000012661 Dyskinesia Diseases 0.000 title 1
- 238000011292 agonist therapy Methods 0.000 title 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5796597P | 1997-09-05 | 1997-09-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL125953A0 true IL125953A0 (en) | 1999-04-11 |
Family
ID=22013812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12595398A IL125953A0 (en) | 1997-09-05 | 1998-08-27 | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20010034345A1 (fr) |
| EP (1) | EP0900567A3 (fr) |
| JP (1) | JP3547624B2 (fr) |
| KR (1) | KR100457756B1 (fr) |
| AU (1) | AU8319398A (fr) |
| CA (1) | CA2246560C (fr) |
| HU (1) | HUP9802022A2 (fr) |
| IL (1) | IL125953A0 (fr) |
| NZ (1) | NZ331636A (fr) |
| TW (1) | TW490304B (fr) |
| ZA (1) | ZA988009B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20005049U1 (de) * | 2000-03-20 | 2000-05-18 | Dewert Antriebs- und Systemtechnik GmbH & Co KG, 32278 Kirchlengern | Elektromotorische Antriebseinheit |
| FR2857594B1 (fr) * | 2003-07-17 | 2005-09-16 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
| EP1604654A1 (fr) * | 2004-05-18 | 2005-12-14 | Schwarz Pharma Ag | Utilisation nouvelle de peptides pour le traitement des dyskynesies |
| CA2603959A1 (fr) * | 2005-04-08 | 2006-10-19 | Eisai R & D Management Co., Ltd. | Agent pour traiter un mouvement involontaire |
| DK2010184T3 (da) * | 2006-04-06 | 2013-03-25 | Nupathe Inc | Implatanter til behandlingen af dopamin associerede tilstande |
| KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4183931A (en) * | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
| WO1992013535A1 (fr) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Quinazolones substituees a activite anticonvulsivante |
| PT101004B (pt) * | 1991-10-26 | 1999-10-29 | Schering Ag | Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem |
| ES2198546T3 (es) * | 1996-05-15 | 2004-02-01 | Pfizer Inc. | 4(3h)-quinazolinonas 2,3,6 trisustituidas. |
-
1998
- 1998-08-20 EP EP98306661A patent/EP0900567A3/fr not_active Withdrawn
- 1998-08-27 IL IL12595398A patent/IL125953A0/xx unknown
- 1998-08-31 NZ NZ331636A patent/NZ331636A/xx unknown
- 1998-09-02 TW TW087114576A patent/TW490304B/zh active
- 1998-09-02 ZA ZA9808009A patent/ZA988009B/xx unknown
- 1998-09-03 CA CA002246560A patent/CA2246560C/fr not_active Expired - Fee Related
- 1998-09-03 JP JP24964498A patent/JP3547624B2/ja not_active Expired - Fee Related
- 1998-09-04 US US09/148,973 patent/US20010034345A1/en not_active Abandoned
- 1998-09-04 HU HU9802022A patent/HUP9802022A2/hu unknown
- 1998-09-04 KR KR10-1998-0036442A patent/KR100457756B1/ko not_active IP Right Cessation
- 1998-09-07 AU AU83193/98A patent/AU8319398A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW490304B (en) | 2002-06-11 |
| EP0900567A2 (fr) | 1999-03-10 |
| AU8319398A (en) | 1999-03-18 |
| JPH11139991A (ja) | 1999-05-25 |
| NZ331636A (en) | 2000-08-25 |
| JP3547624B2 (ja) | 2004-07-28 |
| HU9802022D0 (en) | 1998-10-28 |
| KR100457756B1 (ko) | 2005-04-14 |
| US20010034345A1 (en) | 2001-10-25 |
| CA2246560A1 (fr) | 1999-03-05 |
| KR19990029528A (ko) | 1999-04-26 |
| HUP9802022A2 (hu) | 1999-05-28 |
| CA2246560C (fr) | 2002-12-17 |
| ZA988009B (en) | 2000-03-22 |
| EP0900567A3 (fr) | 2001-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9802021D0 (en) | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | |
| AU2666901A (en) | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
| EP1027011A4 (fr) | Administration d'agents actifs, notamment d'agonistes et antagonistes du recepteur de 5-ht, afin de traiter l'ejaculation precoce | |
| ZA954925B (en) | Delivery of therapeutic agents to receptors using polysaccharides | |
| WO2004058717A8 (fr) | Derives d'isoquinolinone et leur utilisation comme agents therapeutiques | |
| IL142921A0 (en) | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS | |
| WO2001005763A3 (fr) | Composes possedant une activite sur les recepteurs muscariniques | |
| AU2002300464A1 (en) | Apoliprotein A-I Agonist And Their Use To Treat Dyslipidemic Disorders | |
| SG188700A1 (en) | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors | |
| IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
| IL125953A0 (en) | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | |
| SG83723A1 (en) | Novel therapeutic agents that modulate 5ht receptors | |
| IL143385A0 (en) | 5ht1 antagonists for antidepressant therapy | |
| IL206567A0 (en) | Use of an agonist to the igs4 neuromdin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or activity of the igs4 neuromedin receptor ploypeptide | |
| AU7788500A (en) | Use of substance p antagonists for influencing the circadian timing system | |
| HUP0201405A2 (en) | Pharmaceutical composition for therapeutic use of melatonin | |
| AU4856600A (en) | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder | |
| AU2002300534A1 (en) | Methods of Administering an AMPA Receptor Antagonist to Treat Dyskinesias Associated with Dopamine Agonist Therapy | |
| WO2000076500A8 (fr) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| AU2193797A (en) | Delivery of therapeutic agents to the prostate | |
| WO2001046198A3 (fr) | Antagonistes de recepteur opioide kappa non peptidiques | |
| ZA98484B (en) | Use of beta3-adrenergic receptor agonists for the preparation of healing drugs | |
| EP1508337A3 (fr) | Utilisations relatives aux antagonistes et agonistes vis-a-vis du récepteur de la famille Eph pour le traitement des troubles vasculaires | |
| AU8064998A (en) | Fibronectin antagonists as therapeutic agents and broad-spectrum enha ncers of antibiotic therapy | |
| GB9722815D0 (en) | Dopamine D-1 receptor agonist compounds for use in treatment of neurodegenerative diseases |